How to cite item

Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia

   
@article{APS7750,
	author = {Yin Xiao and Hui-hua Hu and Hong-xiang Wang and Xiao-jian Zhu and Ping Zou and Zhi-chao Chen and Zhao-dong Zhong and Wei-ming Li and Yong You},
	title = {Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia},
	journal = {Acta Pharmacologica Sinica},
	volume = {33},
	number = {7},
	year = {2016},
	keywords = {},
	abstract = {Chronic myeloid leukemia (CML) is a malignant hematopoietic stem cell proliferative disease driven by BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome1. Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of CML. Such molecule directed against BCR-ABL firsrt introduced into clinical practice was imatinib mesylate (IM, Gleevec/Glivec, formerly STI571), which showed excellent efficacy in terms of prolonged major molecular response (MMR) and progression-free survival2. Replacing hematopoietic stem cell transplantation, IM is currently recommended as the first-line therapy for CML by the National Comprehensive Cancer Network (NCCN) and European Leukemia Net (ELN).},
	issn = {1745-7254},	url = {http://www.chinaphar.com/article/view/7750}
}